Dragon Pharma, Europe
S23
Oral · 10 mg/tab · 100 tabs
$110.00
Compound ID
Mastorin
Dosage
10–20 mg/day
Concentration
10 mg/tablet
Form
100 Tablets × 10 mg
Half-life
Approximately 12 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma S-23 10mg — High-Potency SARM for Extreme Physique Hardening, Fat Oxidation & Competition Conditioning
Dragon Pharma S-23 10mg, scientifically designated as Mastorin, represents the upper echelon of selective androgen receptor modulator development—a compound engineered for advanced physique athletes who demand steroid-like conditioning without the full spectrum of traditional hormonal complications. Distinguished by its potent anabolic activity, meaningful androgenic character, and unique partial agonism at progesterone receptors, S-23 produces rapid, dramatic transformations in body composition characterized by extreme dryness, grainy muscle density, and pronounced adipose reduction. Dragon Pharma's precisely manufactured 10mg tablets have been independently verified at 12.43mg active content per unit, delivering a marginally overfilled, pharmaceutical-grade product that advanced bodybuilders can deploy with confidence during the most demanding pre-contest and aggressive cutting phases.
What is Dragon Pharma S-23?
S-23 is a non-steroidal selective androgen receptor modulator with an exceptionally high binding affinity for androgen receptors in skeletal muscle and bone tissue. Unlike milder SARMs that operate almost exclusively through anabolic pathways, S-23 exhibits a pharmacological profile closer to dihydrotestosterone derivatives, conferring both robust anabolic and androgenic properties. Its distinctive mechanism includes partial agonism at progesterone receptors, a characteristic absent from most other SARMs, which contributes to its powerful metabolic effects while introducing unique side-effect management considerations. Originally developed as a potential male hormonal contraceptive due to its profound suppressive effects on gonadotropin secretion, S-23 was subsequently recognized by the performance community for its extraordinary ability to strip subcutaneous fluid, accelerate lipolysis, and produce a level of muscular detail typically reserved for advanced anabolic steroid protocols. Dragon Pharma's 10mg oral formulation provides a convenient, accurately dosed delivery vehicle for this formidable agent.
Key Benefits / Effects
- Extreme Muscular Hardening: S-23 aggressively reduces interstitial water retention between muscle fibers and subcutaneous tissue, producing a dry, grainy, and striated appearance unmatched by milder SARMs.
- Accelerated Adipose Oxidation: The compound elevates metabolic rate and shifts substrate utilization toward stored triglycerides, resulting in rapid and visible fat loss even from stubborn deposit areas resistant to conventional dieting.
- Substantial Strength Amplification: Users consistently report explosive increases in compound lift performance, enabling higher training intensities that further stimulate muscular adaptation and caloric expenditure.
- Pronounced Venous Prominence: As subcutaneous water evacuates and adipose thickness decreases, vascularity becomes exceptionally prominent, with veins appearing in previously unseen anatomical locations.
- Lean Tissue Preservation: Despite its powerful fat-loss properties, S-23 maintains a potent anabolic signal that protects contractile muscle mass during aggressive hypocaloric cutting phases.
- Androgenic-Receptor-Mediated Density: The compound's strong androgenic character contributes to neuromuscular efficiency and muscle fiber density, creating a physique that appears carved and three-dimensional rather than merely full.
How Dragon Pharma S-23 Works
S-23 initiates its primary effects through high-affinity binding to androgen receptors in skeletal myocytes, activating genomic pathways that upregulate muscle protein synthesis, satellite cell recruitment, and myonuclear domain expansion. Simultaneously, its partial agonism at progesterone receptors modulates metabolic gene expression in ways that enhance lipolytic enzyme activity and reduce estrogen-mediated water retention. The compound's strong androgenic character increases neuromuscular transmission efficiency and contractile force generation, while its suppressive effects on luteinizing hormone and follicle-stimulating hormone—originally observed in contraceptive research—underscore the depth of its endocrine impact. The net physiological outcome is a rapid recomposition environment where adipose tissue is mobilized for fuel, subcutaneous fluid is minimized, and muscle fibers become progressively denser and more defined. This multi-receptor activity creates an anabolic milieu that bridges the gap between traditional SARMs and hardening anabolic steroids.
Usage Information
Dragon Pharma S-23 is supplied as 10mg oral tablets with a pharmacokinetic half-life of approximately 12–16 hours, necessitating split-dose administration for stable plasma concentrations and consistent receptor activation. Due to its extreme potency, significant suppressive nature, and advanced side-effect profile, S-23 is strictly contraindicated for novice users. Intermediate and advanced practitioners typically initiate at 10mg daily, divided into two 5mg doses spaced roughly 8 hours apart. Experienced users may escalate to 15–20mg daily, while expert-level protocols reaching 20–25mg daily produce dramatic results but substantially increase suppression severity and organ stress. Cycle duration must be strictly limited to 6–8 weeks due to hepatotoxicity and profound hypothalamic-pituitary-gonadal axis shutdown. A comprehensive Post-Cycle Therapy protocol is absolutely mandatory, and a testosterone base is strongly recommended to prevent severe low-androgen symptoms during the cycle. Dosing with food may improve tolerability and reduce gastrointestinal irritation.
Quality & Manufacturing
Dragon Pharma maintains uncompromising manufacturing and analytical standards, with each S-23 batch subjected to independent third-party laboratory testing for identity, purity, and potency verification. Recent analytical results confirmed an actual S-23 content of 12.43mg per tablet—a meaningful overfill that ensures users receive the full intended pharmacological impact of this potent compound. In the advanced SARM marketplace, where underdosing and mislabeling are rampant, this level of dosing accuracy is critical. A product falling short of its labeled claim would fail to produce the extreme hardening and fat-loss effects advanced users expect, while an unpredictably overdosed alternative could expose athletes to dangerous levels of suppression and hepatotoxicity. Dragon Pharma's commitment to analytical transparency provides the precision required for safe, effective integration of this formidable agent into sophisticated physique-enhancement protocols.
Possible Side Effects / Safety Information
- Profound Testosterone Suppression: S-23 exerts severe negative feedback on the hypothalamic-pituitary-gonadal axis, frequently producing complete shutdown of endogenous testosterone synthesis even at moderate doses. A testosterone base and aggressive PCT are mandatory.
- Androgenic Manifestations: Users may experience acne vulgaris, accelerated male pattern baldness in genetically predisposed individuals, and increased terminal hair growth due to the compound's strong androgenic activity.
- Progestogenic Gynecomastia Risk: Partial progesterone receptor agonism can contribute to mammary tissue development in sensitive individuals, particularly when stacked with aromatizing compounds. An aromatase inhibitor and prolactin management strategy should be available.
- Hepatic Stress: As a C17-alpha alkylated oral compound, S-23 places significant strain on liver enzyme systems. Cycle length must not exceed 8 weeks, and dedicated liver support with TUDCA and NAC is essential.
- Dyslipidemia: The compound can substantially depress HDL cholesterol while elevating LDL cholesterol and triglycerides, necessitating cardiovascular monitoring and dietary intervention.
- Vision Disturbances: Some users report mild, temporary difficulty with dark adaptation or visual tinting, similar to but typically less severe than effects associated with S4 (Andarine).
- Hypotensive and Lethargic Symptoms: Deep suppression can produce low-energy states, joint discomfort, and diminished libido in the absence of a testosterone base.
Why Choose Dragon Pharma S-23?
Advanced physique enhancement demands compounds that operate at the extreme edge of efficacy, and product integrity becomes non-negotiable when manipulating agents of this potency. Dragon Pharma's verified 12.43mg per tablet—significantly exceeding the 10mg label claim—guarantees that users receive the full, uncompromising pharmacological payload required for competition-level conditioning. In a marketplace saturated with underdosed Mastorin alternatives and mislabeled research chemicals, this analytical precision protects athletes from the dual frustrations of ineffective cycles and unpredictable toxicity. For bodybuilders preparing for the stage, physique competitors seeking extreme dryness, or advanced athletes pursuing steroid-like recomposition without full hormonal conversion, Dragon Pharma S-23 delivers a verified, elite-grade tool capable of producing the most aggressive hardening and fat-loss results available within the SARM category.
Product FAQ
Questions, answered
S-23 occupies a distinctly more aggressive position on the potency spectrum. While RAD-140 emphasizes strength and LGD-4033 prioritizes lean mass volume, S-23 is uniquely optimized for extreme dryness, density, and fat loss. Its androgenic and progestogenic properties produce effects closer to hardening steroids like Masteron or Winstrol than to conventional SARMs. The trade-off is significantly greater suppression, hepatotoxicity, and side-effect burden, making it suitable only for advanced users with extensive prior experience.
No. S-23 is explicitly contraindicated for beginners and generally discouraged for users with fewer than several prior SARM or anabolic steroid cycles. Its profound suppressive nature, liver stress, androgenic side effects, and requirement for testosterone bases, aromatase inhibitors, and comprehensive PCT make it an advanced-only compound. Novices should develop their understanding of hormonal response, suppression management, and organ protection through milder agents before considering S-23.
S-23's suppressive potency rapidly depletes endogenous testosterone, producing severe low-androgen symptoms including lethargy, joint pain, diminished libido, erectile dysfunction, and mood disturbances. A testosterone base—typically 200–400mg weekly of Testosterone Enanthate or Cypionate—maintains physiological androgen levels, preventing these debilitating symptoms while allowing S-23 to exert its unique hardening and fat-loss effects. Because exogenous testosterone aromatizes to estrogen, an aromatase inhibitor like Exemestane should be kept available to manage estrogenic sides.
Yes. Unlike most SARMs, S-23 exhibits partial progesterone receptor agonism, which can contribute to mammary tissue proliferation in sensitive individuals—particularly when stacked with aromatizing compounds. Users should monitor for nipple sensitivity, swelling, or subareolar lumps. Management strategies include maintaining an aromatase inhibitor on hand, keeping estrogen from any testosterone base within normal range, and having Cabergoline available for prolactin modulation if progestogenic symptoms emerge.
For competition-level dryness and detail, stack S-23 with YK-11 to maximize myostatin inhibition and muscle density, plus GW501516 (Cardarine) to sustain endurance through demanding cardio sessions. This trio creates an environment of extreme fat oxidation, subcutaneous water reduction, and grainy muscularity. A testosterone propionate base should underpin the stack, with daily aromatase inhibitor management. This combination is among the most aggressive non-steroid-heavy protocols available for stage-ready conditioning.
S-23 can produce significant negative shifts in lipid profiles, including marked HDL depression and LDL elevation. This dyslipidemic effect, combined with potential blood pressure fluctuations from rapid body recomposition, necessitates cardiovascular vigilance. Users should supplement with high-dose omega-3 fatty acids, maintain dietary fiber intake, incorporate regular low-intensity cardio, and obtain pre-cycle, mid-cycle, and post-cycle lipid panels to monitor hepatic and cardiovascular status.
Given its C17-alpha alkylated structure, S-23 requires dedicated hepatoprotection. Standard protocols include TUDCA at 500mg daily and N-acetylcysteine (NAC) at 1200–2400mg daily. Avoidance of alcohol, acetaminophen, and other hepatotoxic agents is mandatory. Pre-cycle liver enzyme baselines (ALT, AST, GGT) should be established, with mid-cycle monitoring at week 4 to assess hepatic stress. Cycle length must never exceed 8 weeks regardless of liver marker status.
PCT must be aggressive due to the depth of suppression. A comprehensive protocol includes Clomiphene Citrate at 50/50/25/25mg and Tamoxifen Citrate at 40/20/20/20mg over four weeks. For users who employed a testosterone base, PCT timing should account for ester clearance. HCG at 500–1000IU every other day for the two weeks preceding SERM initiation can prime testicular responsiveness. Blood work confirming recovered LH, FSH, and total testosterone should be obtained before initiating any subsequent cycle.
Some users report mild, temporary difficulty with dark adaptation or subtle visual tinting while using S-23, though these effects are generally less pronounced and less frequent than those associated with S4. The mechanism likely involves minor off-target activity on retinal enzymes. These symptoms typically resolve spontaneously upon discontinuation. Users experiencing persistent visual disturbances should cease administration immediately and consult an ophthalmologist.
Most users report subjective improvements in muscle hardness, training aggression, and vascularity within the first 7–10 days. Visible fat loss and subcutaneous water reduction typically consolidate by weeks 2–3, with maximal dryness, density, and striation appearing in the final weeks of the 6–8 week cycle. Because S-23 produces genuinely dry tissue changes rather than fluid-mediated bulk, the physique transformations are slower to initiate than wet compounds but yield substantially more permanent and aesthetically refined results.
